journal article·2016-11-16Open access

Development of PEGylated solid lipid nanoparticles of pentoxifylline for their beneficial pharmacological potential in pathological cardiac hypertrophy

Sunny Dhiman, Neeraj Mishra, Saurabh Sharma

Abstract

Objective: The present study was designed to develop PEGylated solid lipid nanoparticles (SLNs) of pentoxifylline (with increased t½) for the management of cardiac hypertrophy. Materials and methods: PEGylated SLNs were prepared by melt emulsification method and characterised by zeta potential, polydispersity index, entrapment efficiency, in vitro release and pharmacokinetic profile. Hypertrophy was assessed as increase in tumour necrosis factor-alpha, mean arterial blood pressure, LV protein content and left ventricular end diastolic pressure. Result: PEGylated SLNs (F19) with increased t½ were developed and characterised. F19 attenuates hypertrophy assessed in terms of parameters employed. Conclusion: Thus, PEGylated SLNs (F19) of pentoxifylline have enhanced t½ and consequently more significantly preclude cardiac hypertrophy as compared to pentoxifylline.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Caveolin-1 and cellular processes · Nanoparticle-Based Drug Delivery · Advancements in Transdermal Drug Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (30)

Show source-provided references
1. 10.1021/mp800051m10.1021/mp800051m ↗
2. Balakumar P · Iran J Pharmacol Ther · 2005 · 4 · 138
3. 10.1111/1755-5922.1207610.1111/1755-5922.12076 ↗
4. 10.1007/s11095-011-0510-x10.1007/s11095-011-0510-x ↗
5. Chmielewska A · Acta Chromatogr · 2006 · 16 · 70
6. 10.1111/j.1751-7915.2008.00028.x10.1111/j.1751-7915.2008.00028.x ↗
7. 10.1161/01.HYP.0000118584.33350.7d10.1161/01.HYP.0000118584.33350.7d ↗
8. 10.1046/j.1440-1681.2003.03917.x10.1046/j.1440-1681.2003.03917.x ↗
9. 10.1902/jop.2004.75.1.16210.1902/jop.2004.75.1.162 ↗
10. 10.1161/CIRCULATIONAHA.109.19266710.1161/CIRCULATIONAHA.109.192667 ↗
11. 10.1021/nn203745n10.1021/nn203745n ↗
12. 10.1111/j.1527-5299.2007.06624.x10.1111/j.1527-5299.2007.06624.x ↗
13. 10.1046/j.1365-2567.1997.00246.x10.1046/j.1365-2567.1997.00246.x ↗
14. 10.1016/S0939-6411(00)00087-410.1016/S0939-6411(00)00087-4 ↗
15. Nunes S · J Mol Pharm Org Process Res · 2015 · 3 · e120
16. Parhi R · J Chem Pharm Res · 2010 · 2 · 211
17. 10.1016/j.ijpharm.2012.07.00610.1016/j.ijpharm.2012.07.006 ↗
18. 10.1017/S104795111400081X10.1017/S104795111400081X ↗
19. 10.1002/jps.260075011110.1002/jps.2600750111 ↗
20. 10.1161/CIRCULATIONAHA.106.64358510.1161/CIRCULATIONAHA.106.643585 ↗
21. 10.3109/0898210090316145610.3109/08982100903161456 ↗
22. 10.1016/j.jconrel.2004.01.00510.1016/j.jconrel.2004.01.005 ↗
23. 10.1038/nnano.2014.1710.1038/nnano.2014.17 ↗
24. 10.1007/978-1-59745-198-7_210.1007/978-1-59745-198-7_2 ↗
25. 10.1016/j.jbiotec.2009.05.01210.1016/j.jbiotec.2009.05.012 ↗
26. 10.3390/molecules18111334010.3390/molecules181113340 ↗
27. 10.1152/ajpheart.00178.200510.1152/ajpheart.00178.2005 ↗
28. 10.1016/j.bbrc.2004.11.13110.1016/j.bbrc.2004.11.131 ↗
29. Zhao Y · Int J Nanomed · 2012 · 7 · 2891
30. Zou Y · Chin J Pharm · 2012 · 43 · 438